Novo Nordisk’s GLP weight-loss drug Ozempic has been linked to a rare form of vision loss called non-arteritic anterior ischemic optic neuropathy (NAION). A study published on medRxiv found this association, which aligns with earlier findings from Harvard University.
The company’s stock performance is also being watched closely. Market Domination hosts Julie Hyman and Josh Lipton will discuss the implications of these findings and Novo Nordisk’s year-to-date results in a forthcoming episode.
Source: https://finance.yahoo.com/video/novo-nordisks-ozempic-reportedly-linked-205401200.html